Genocea Biosciences Inc (NASDAQ:GNCA) Director George Siber purchased 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 29th. The shares were bought at an average cost of $0.61 per share, with a total value of $15,250.00. Following the completion of the acquisition, the director now owns 27,017 shares of the company’s stock, valued at $16,480.37. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

George Siber also recently made the following trade(s):

  • On Thursday, September 6th, George Siber purchased 25,000 shares of Genocea Biosciences stock. The shares were bought at an average cost of $0.61 per share, with a total value of $15,250.00.
  • On Tuesday, September 4th, George Siber acquired 25,000 shares of Genocea Biosciences stock. The stock was acquired at an average price of $0.62 per share, with a total value of $15,500.00.
  • On Friday, August 31st, George Siber acquired 25,000 shares of Genocea Biosciences stock. The stock was acquired at an average price of $0.61 per share, with a total value of $15,250.00.

NASDAQ:GNCA opened at $0.72 on Wednesday. The firm has a market capitalization of $47.64 million, a price-to-earnings ratio of -0.36 and a beta of 1.03. The company has a debt-to-equity ratio of 0.95, a current ratio of 6.84 and a quick ratio of 6.84. Genocea Biosciences Inc has a 1 year low of $0.49 and a 1 year high of $2.15.

Genocea Biosciences (NASDAQ:GNCA) last released its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.02. sell-side analysts anticipate that Genocea Biosciences Inc will post -0.47 EPS for the current year.

Hedge funds have recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of Genocea Biosciences by 169.1% in the first quarter. BlackRock Inc. now owns 3,960,353 shares of the biotechnology company’s stock valued at $4,159,000 after buying an additional 2,488,540 shares in the last quarter. California State Teachers Retirement System increased its position in shares of Genocea Biosciences by 166.6% in the first quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 78,469 shares in the last quarter. Northern Trust Corp increased its position in shares of Genocea Biosciences by 164.5% in the first quarter. Northern Trust Corp now owns 792,677 shares of the biotechnology company’s stock valued at $833,000 after buying an additional 492,961 shares in the last quarter. DRW Securities LLC purchased a new position in shares of Genocea Biosciences in the second quarter valued at $205,000. Finally, Schwab Charles Investment Management Inc. purchased a new position in shares of Genocea Biosciences in the first quarter valued at $177,000. Institutional investors and hedge funds own 60.23% of the company’s stock.

Several research analysts have issued reports on the company. Zacks Investment Research cut Genocea Biosciences from a “hold” rating to a “sell” rating in a research report on Wednesday, July 11th. ValuEngine upgraded Genocea Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Finally, HC Wainwright set a $5.00 price objective on Genocea Biosciences and gave the stock a “buy” rating in a research report on Thursday, August 2nd. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company’s stock. Genocea Biosciences currently has a consensus rating of “Buy” and an average target price of $4.68.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Featured Story: Day Trading – Risk Worth the Reward?

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.